+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Respiratory Infection Diagnostics Market - Global Forecast to 2030- Product Image
Respiratory Infection Diagnostics Market - Global Forecast to 2030- Product Image
Sale

Respiratory Infection Diagnostics Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 183 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6012371
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Respiratory Infection Diagnostics Market grew from USD 82.35 billion in 2024 to USD 88.38 billion in 2025. It is expected to continue growing at a CAGR of 7.18%, reaching USD 124.87 billion by 2030.

The field of respiratory infection diagnostics has undergone a remarkable evolution in recent years, driven by the urgent need to accurately detect pathogens and guide patient management. Innovations in molecular technologies, immunoassays, and automated microbiology platforms have expanded testing capabilities beyond traditional culture techniques. Concurrently, the emergence of novel viral threats and the persistence of endemic pathogens have underscored the importance of rapid, reliable diagnostics to reduce transmission and improve clinical outcomes. As health systems worldwide adapt to shifting epidemiological landscapes, the convergence of advanced laboratory infrastructure, digital health tools, and point-of-care solutions is reshaping diagnostic pathways. This introduction provides a comprehensive overview of the major drivers influencing market growth, sets the stage for examining regulatory and trade challenges, and highlights the strategic importance of segmentation and regional dynamics in informing investment and product development decisions.

Transformative Shifts Reshaping Diagnostic Pathways

Over the past few years, several transformative shifts have redefined respiratory infection diagnostics. First, the widespread adoption of nucleic acid amplification assays has accelerated pathogen detection times from days to hours, enabling clinicians to make informed treatment decisions more rapidly. Second, integration of isothermal amplification methods into portable platforms has facilitated decentralization of testing, particularly in resource-limited settings and at the point of care. Third, the proliferation of digital connectivity solutions has allowed remote monitoring of test performance and seamless integration with electronic health records, enhancing case management and epidemiological surveillance. Fourth, the COVID-19 pandemic catalyzed unprecedented collaboration across industry, academia, and government, resulting in streamlined regulatory pathways and greater investment in assay development. Finally, the focus on multiplexed panels capable of detecting multiple respiratory pathogens in a single run underscores a shift toward comprehensive diagnostic profiles. These collective changes are setting new benchmarks for diagnostic accuracy, turnaround time, and accessibility.

Assessing the 2025 U.S. Tariff Impact on Supply Chains

In 2025, the imposition of new tariffs on imported reagents, instruments, and consumables in the United States will introduce significant cost pressures across the supply chain. Diagnostic manufacturers reliant on raw materials sourced from global partners will face increased production expenses, potentially leading to higher list prices for end users. Healthcare providers may respond by prioritizing high-value tests and negotiating volume-based rebates to mitigate budgetary constraints. Meanwhile, domestic producers stand to benefit from protective measures, potentially attracting investment to local manufacturing sites and fostering innovation in reagent formulation and instrument design. However, supply chain realignment could also lead to temporary disruptions as logistics networks adapt to new trade regulations. To navigate this evolving landscape, stakeholders must evaluate alternative sourcing strategies, invest in regional distribution hubs, and explore collaborative agreements that ensure continuity of supply while maintaining affordability and quality.

Comprehensive Segmentation Insights Across Multiple Domains

An in-depth segmentation analysis reveals differentiated growth trajectories across test types, diagnostic technologies, patient populations, clinical indications, usage settings, and end users. Clinical microbiology testing, encompassing fully automated instruments and culture media protocols, remains fundamental for pathogen isolation, while molecular diagnostics technologies-spanning polymerase chain reaction, next-generation sequencing, microarray panels, and isothermal nucleic acid amplification-drive demand for rapid, high-sensitivity assays. Serology and immunoassay platforms, including enzyme-linked immunosorbent assays and rapid diagnostic tests, continue to serve as cost-effective screening tools. Advanced diagnostic techniques, such as antigen detection and genomic profiling, are gaining traction against traditional methodologies like direct smear microscopy, owing to their superior throughput and analytical precision. From a patient perspective, adult cohorts account for the bulk of test volumes, but geriatric and pediatric segments exhibit unique epidemiological patterns and testing needs. Acute respiratory infections-covering common cold, influenza, and COVID-19-dominate demand, yet chronic conditions such as asthma and chronic obstructive pulmonary disease drive year-round monitoring. In hospital laboratories, point-of-care testing sites, and research institutions, differentiated workflows influence instrument procurement, staffing models, and capital investment cycles. Finally, diagnostic centers, homecare providers, inpatient and outpatient facilities within hospitals and clinics, and research institutes each maintain distinct purchasing criteria shaped by throughput requirements, regulatory certification, and cost sensitivity.

Key Regional Dynamics Influencing Adoption

Regional dynamics play a pivotal role in shaping market potential and adoption strategies. In the Americas, strong reimbursement frameworks, established laboratory networks, and high healthcare expenditure underpin robust demand for advanced molecular assays and multiplex panels. Regulatory harmonization efforts continue to streamline market entry, although persistent disparities in rural and underserved areas call for expanded point-of-care solutions. The Europe, Middle East & Africa region presents a heterogenous mix of mature diagnostics markets in Western Europe, emerging growth opportunities in Eastern Europe, and variable infrastructure in Middle Eastern and African nations. Demand drivers here include pandemic preparedness programs, antimicrobial resistance surveillance initiatives, and capacity building in reference laboratories. In Asia-Pacific, rapid economic development, rising awareness of respiratory health, and government-led screening campaigns in markets such as China, India, and Southeast Asia are fueling investments in both centralized and decentralized testing modalities. Local manufacturing partnerships and in-country regulatory pathways further influence the competitive landscape and speed of product launches across these diverse markets.

Competitive Landscape and Leading Industry Players

Leading players in the respiratory infection diagnostics arena are leveraging complementary portfolios and strategic initiatives to capture market share. Abbott Laboratories harnesses its global footprint and integrated immunoassay platforms to expand respiratory panels, while AccuBioTech Co. Ltd. is intensifying its focus on cost-effective molecular kits tailored for emerging markets. Atomo Diagnostics Ltd. specializes in user-friendly rapid tests for decentralized settings, and Becton, Dickinson and Company combines automated microbiology systems with data analytics solutions. Bio-Rad Laboratories Inc. and bioMérieux SA continue to innovate culture media and immunoassays, respectively, to address evolving pathogen profiles. BIORON Diagnostics GmbH advances isothermal amplification assays for high-throughput laboratories, whereas Cardinal Health Inc. leverages distribution capabilities to ensure timely kit availability. Chembio Diagnostics, Inc. differentiates through dual-pathogen rapid tests, and F. Hoffmann-La Roche Ltd. excels in multiplex PCR panels. Hologic, Inc. drives integration of diagnostic platforms with digital lab management, while Merck KGaA invests in reagent technologies for molecular and serological applications. Meridian Bioscience Inc. by SD Biosensor focuses on point-of-care immunodiagnostics, Quest Diagnostics Incorporated operates one of the largest testing networks in North America, and Quidel Corporation enhances its offerings with advanced immunofluorescence assays. Together, these companies set benchmarks in assay sensitivity, workflow efficiency, and global reach.

Actionable Recommendations for Market Leadership

Industry leaders must adopt a multifaceted approach to capitalize on accelerating market opportunities. First, prioritizing modular platform development ensures scalability across laboratory tiers and facilitates rapid assay integration as new pathogens emerge. Second, fostering cross-sector partnerships with academic institutions and public health agencies can streamline validation studies and enhance surveillance capabilities. Third, investing in localized manufacturing and distribution networks mitigates supply chain vulnerabilities exacerbated by tariff changes and geopolitical tensions. Fourth, cultivating digital ecosystems that connect testing devices with informatics solutions will drive value-based care models and real-time epidemiological insights. Fifth, developing tailored test menus that address the specific needs of pediatric, geriatric, and chronic disease cohorts can unlock niche segments and deliver differentiated patient outcomes. Finally, embedding sustainable practices in reagent formulation, packaging, and instrument lifecycle management supports environmental stewardship and resonates with increasingly eco-conscious stakeholders.

Conclusion and Strategic Outlook

The respiratory infection diagnostics landscape is poised for sustained growth as technological innovation, regulatory evolution, and shifting healthcare priorities converge. Rapid molecular assays and decentralized testing modalities will redefine diagnostic paradigms, while strategic adaptation to trade policies and supply chain realignment will prove critical for maintaining operational resilience. Detailed segmentation and regional insights underscore the importance of nuanced strategies that address the unique demands of distinct test types, patient populations, and healthcare infrastructures. Collaboration across industry, academia, and public health entities will remain essential to advance assay performance and ensure equitable access. Executing on these strategic imperatives will position organizations to deliver impactful diagnostic solutions that improve patient outcomes and strengthen global health security.

Market Segmentation & Coverage

This research report categorizes the Respiratory Infection Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Clinical Microbiology Testing
    • Automated & Semi-Automated Instruments
    • Culture Media Testing
  • Molecular Diagnostics
    • Isothermal Nucleic Acid Amplification
    • Microarray
    • Next-Generation Sequencing
    • Polymerase Chain Reaction
  • Serology & Immunoassays
    • Enzyme-Linked Immunosorbent Assay
    • Rapid Diagnostic Tests
  • Advanced Diagnostic Techniques
    • Antigen Detection Techniques
    • Genomic Testing Techniques
  • Traditional Diagnostic Techniques
    • Direct Smear Microscopy
  • Adult
  • Geriatric
  • Pediatric
  • Acute Respiratory Infections
    • Common Cold
    • COVID-19
    • Influenza
  • Chronic Respiratory Conditions
    • Asthma
    • Chronic Obstructive Pulmonary Disease
  • Hospital Laboratories
  • Point of Care Testing
  • Research Laboratories
  • Diagnostic Centers
  • Homecare
  • Hospitals & Clinics
    • Inpatient Facilities
    • Outpatient Settings
  • Research Institutes

This research report categorizes the Respiratory Infection Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Respiratory Infection Diagnostics Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abbott Laboratories
  • AccuBioTech Co. Ltd.
  • Atomo Diagnostics Ltd.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories Inc.
  • bioMerieux SA
  • BIORON Diagnostics GmbH
  • Cardinal Health Inc.
  • Chembio Diagnostics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Merck KGaA
  • Meridian Bioscience Inc. by SD Biosensor
  • Quest Diagnostics Incorporated
  • Quidel Corporation

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Respiratory Infection Diagnostics Market, by Test Type
8.1. Introduction
8.2. Clinical Microbiology Testing
8.2.1. Automated & Semi-Automated Instruments
8.2.2. Culture Media Testing
8.3. Molecular Diagnostics
8.3.1. Isothermal Nucleic Acid Amplification
8.3.2. Microarray
8.3.3. Next-Generation Sequencing
8.3.4. Polymerase Chain Reaction
8.4. Serology & Immunoassays
8.4.1. Enzyme-Linked Immunosorbent Assay
8.4.2. Rapid Diagnostic Tests
9. Respiratory Infection Diagnostics Market, by Diagnostic Technology
9.1. Introduction
9.2. Advanced Diagnostic Techniques
9.2.1. Antigen Detection Techniques
9.2.2. Genomic Testing Techniques
9.3. Traditional Diagnostic Techniques
9.3.1. Direct Smear Microscopy
10. Respiratory Infection Diagnostics Market, by Patient Type
10.1. Introduction
10.2. Adult
10.3. Geriatric
10.4. Pediatric
11. Respiratory Infection Diagnostics Market, by Condition
11.1. Introduction
11.2. Acute Respiratory Infections
11.2.1. Common Cold
11.2.2. COVID-19
11.2.3. Influenza
11.3. Chronic Respiratory Conditions
11.3.1. Asthma
11.3.2. Chronic Obstructive Pulmonary Disease
12. Respiratory Infection Diagnostics Market, by Usage Setting
12.1. Introduction
12.2. Hospital Laboratories
12.3. Point of Care Testing
12.4. Research Laboratories
13. Respiratory Infection Diagnostics Market, by End User
13.1. Introduction
13.2. Diagnostic Centers
13.3. Homecare
13.4. Hospitals & Clinics
13.4.1. Inpatient Facilities
13.4.2. Outpatient Settings
13.5. Research Institutes
14. Americas Respiratory Infection Diagnostics Market
14.1. Introduction
14.2. Argentina
14.3. Brazil
14.4. Canada
14.5. Mexico
14.6. United States
15. Asia-Pacific Respiratory Infection Diagnostics Market
15.1. Introduction
15.2. Australia
15.3. China
15.4. India
15.5. Indonesia
15.6. Japan
15.7. Malaysia
15.8. Philippines
15.9. Singapore
15.10. South Korea
15.11. Taiwan
15.12. Thailand
15.13. Vietnam
16. Europe, Middle East & Africa Respiratory Infection Diagnostics Market
16.1. Introduction
16.2. Denmark
16.3. Egypt
16.4. Finland
16.5. France
16.6. Germany
16.7. Israel
16.8. Italy
16.9. Netherlands
16.10. Nigeria
16.11. Norway
16.12. Poland
16.13. Qatar
16.14. Russia
16.15. Saudi Arabia
16.16. South Africa
16.17. Spain
16.18. Sweden
16.19. Switzerland
16.20. Turkey
16.21. United Arab Emirates
16.22. United Kingdom
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Abbott Laboratories
17.3.2. AccuBioTech Co. Ltd.
17.3.3. Atomo Diagnostics Ltd.
17.3.4. Becton, Dickinson and Company
17.3.5. Bio-Rad Laboratories Inc.
17.3.6. bioMerieux SA
17.3.7. BIORON Diagnostics GmbH
17.3.8. Cardinal Health Inc.
17.3.9. Chembio Diagnostics, Inc.
17.3.10. F. Hoffmann-La Roche Ltd.
17.3.11. Hologic, Inc.
17.3.12. Merck KGaA
17.3.13. Meridian Bioscience Inc. by SD Biosensor
17.3.14. Quest Diagnostics Incorporated
17.3.15. Quidel Corporation
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. RESPIRATORY INFECTION DIAGNOSTICS MARKET MULTI-CURRENCY
FIGURE 2. RESPIRATORY INFECTION DIAGNOSTICS MARKET MULTI-LANGUAGE
FIGURE 3. RESPIRATORY INFECTION DIAGNOSTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CONDITION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CONDITION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY USAGE SETTING, 2024 VS 2030 (%)
FIGURE 16. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY USAGE SETTING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. RESPIRATORY INFECTION DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. RESPIRATORY INFECTION DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. RESPIRATORY INFECTION DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CLINICAL MICROBIOLOGY TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY AUTOMATED & SEMI-AUTOMATED INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CULTURE MEDIA TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CLINICAL MICROBIOLOGY TESTING, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEROLOGY & IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEROLOGY & IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ADVANCED DIAGNOSTIC TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ANTIGEN DETECTION TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY GENOMIC TESTING TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ADVANCED DIAGNOSTIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DIRECT SMEAR MICROSCOPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ACUTE RESPIRATORY INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COMMON COLD, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COVID-19, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ACUTE RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY USAGE SETTING, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INPATIENT FACILITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY OUTPATIENT SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CLINICAL MICROBIOLOGY TESTING, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEROLOGY & IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ADVANCED DIAGNOSTIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ACUTE RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY USAGE SETTING, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CLINICAL MICROBIOLOGY TESTING, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEROLOGY & IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ADVANCED DIAGNOSTIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ACUTE RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY USAGE SETTING, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CLINICAL MICROBIOLOGY TESTING, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEROLOGY & IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ADVANCED DIAGNOSTIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ACUTE RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY USAGE SETTING, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 98. CANADA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 99. CANADA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CLINICAL MICROBIOLOGY TESTING, 2018-2030 (USD MILLION)
TABLE 100. CANADA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 101. CANADA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEROLOGY & IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 102. CANADA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 103. CANADA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ADVANCED DIAGNOSTIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 104. CANADA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 105. CANADA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 106. CANADA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 107. CANADA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ACUTE RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 108. CANADA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 109. CANADA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY USAGE SETTING, 2018-2030 (USD MILLION)
TABLE 110. CANADA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. CANADA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 112. MEXICO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 113. MEXICO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CLINICAL MICROBIOLOGY TESTING, 2018-2030 (USD MILLION)
TABLE 114. MEXICO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 115. MEXICO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEROLOGY & IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 116. MEXICO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 117. MEXICO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ADVANCED DIAGNOSTIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 118. MEXICO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 119. MEXICO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 120. MEXICO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 121. MEXICO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ACUTE RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 122. MEXICO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 123. MEXICO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY USAGE SETTING, 2018-2030 (USD MILLION)
TABLE 124. MEXICO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. MEXICO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 126. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 127. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CLINICAL MICROBIOLOGY TESTING, 2018-2030 (USD MILLION)
TABLE 128. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 129. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEROLOGY & IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 130. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 131. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ADVANCED DIAGNOSTIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 132. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 133. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 134. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 135. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ACUTE RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 136. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 137. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY USAGE SETTING, 2018-2030 (USD MILLION)
TABLE 138. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 140. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 141. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 142. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CLINICAL MICROBIOLOGY TESTING, 2018-2030 (USD MILLION)
TABLE 143. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 144. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEROLOGY & IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 145. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 146. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ADVANCED DIAGNOSTIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 147. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 148. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 149. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 150. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ACUTE RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 151. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 152. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY USAGE SETTING, 2018-2030 (USD MILLION)
TABLE 153. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 155. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 156. AUSTRALIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 157. AUSTRALIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CLINICAL MICROBIOLOGY TESTING, 2018-2030 (USD MILLION)
TABLE 158. AUSTRALIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 159. AUSTRALIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEROLOGY & IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 160. AUSTRALIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 161. AUSTRALIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ADVANCED DIAGNOSTIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 162. AUSTRALIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 163. AUSTRALIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 164. AUSTRALIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 165. AUSTRALIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ACUTE RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 166. AUSTRALIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 167. AUSTRALIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY USAGE SETTING, 2018-2030 (USD MILLION)
TABLE 168. AUSTRALIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. AUSTRALIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 170. CHINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 171. CHINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CLINICAL MICROBIOLOGY TESTING, 2018-2030 (USD MILLION)
TABLE 172. CHINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 173. CHINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEROLOGY & IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 174. CHINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 175. CHINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ADVANCED DIAGNOSTIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 176. CHINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 177. CHINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 178. CHINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 179. CHINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ACUTE RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 180. CHINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 181. CHINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY USAGE SETTING, 2018-2030 (USD MILLION)
TABLE 182. CHINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. CHINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 184. INDIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 185. INDIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CLINICAL MICROBIOLOGY TESTING, 2018-2030 (USD MILLION)
TABLE 186. INDIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 187. INDIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEROLOGY & IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 188. INDIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 189. INDIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ADVANCED DIAGNOSTIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 190. INDIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 191. INDIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 192. INDIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 193. INDIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ACUTE RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 194. INDIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 195. INDIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY USAGE SETTING, 2018-2030 (USD MILLION)
TABLE 196. INDIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. INDIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 198. INDONESIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 199. INDONESIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CLINICAL MICROBIOLOGY TESTING, 2018-2030 (USD MILLION)
TABLE 200. INDONESIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 201. INDONESIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEROLOGY & IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 202. INDONESIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 203. INDONESIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ADVANCED DIAGNOSTIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 204. INDONESIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 205. INDONESIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 206. INDONESIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 207. INDONESIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ACUTE RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 208. INDONESIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 209. INDONESIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY USAGE SETTING, 2018-2030 (USD MILLION)
TABLE 210. INDONESIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. INDONESIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 212. JAPAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 213. JAPAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CLINICAL MICROBIOLOGY TESTING, 2018-2030 (USD MILLION)
TABLE 214. JAPAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 215. JAPAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEROLOGY & IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 216. JAPAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 217. JAPAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ADVANCED DIAGNOSTIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 218. JAPAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 219. JAPAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 220. JAPAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 221. JAPAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ACUTE RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 222. JAPAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 223. JAPAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY USAGE SETTING, 2018-2030 (USD MILLION)
TABLE 224. JAPAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 225. JAPAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 226. MALAYSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 227. MALAYSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CLINICAL MICROBIOLOGY TESTING, 2018-2030 (USD MILLION)
TABLE 228. MALAYSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 229. MALAYSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEROLOGY & IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 230. MALAYSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 231. MALAYSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ADVANCED DIAGNOSTIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 232. MALAYSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 233. MALAYSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 234. MALAYSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 235. MALAYSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ACUTE RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 236. MALAYSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 237. MALAYSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY USAGE SETTING, 2018-2030 (USD MILLION)
TABLE 238. MALAYSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 239. MALAYSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 240. PHILIPPINES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 241. PHILIPPINES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CLINICAL MICROBIOLOGY TESTING, 2018-2030 (USD MILLION)
TABLE 242. PHILIPPINES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 243. PHILIPPINES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEROLOGY & IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 244. PHILIPPINES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 245. PHILIPPINES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ADVANCED DIAGNOSTIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 246. PHILIPPINES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 247. PHILIPPINES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 248. PHILIPPINES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 249. PHILIPPINES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ACUTE RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 250. PHILIPPINES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 251. PHILIPPINES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY USAGE SETTING, 2018-2030 (USD MILLION)
TABLE 252. PHILIPPINES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 253. PHILIPPINES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 254. SINGAPORE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 255. SINGAPORE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CLINICAL MICROBIOLOGY TESTING, 2018-2030 (USD MILLION)
TABLE 256. SINGAPORE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 257. SINGAPORE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEROLOGY & IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 258. SINGAPORE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 259. SINGAPORE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ADVANCED DIAGNOSTIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 260. SINGAPORE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 261. SINGAPORE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 262. SINGAPORE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 263. SINGAPORE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ACUTE RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 264. SINGAPORE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 265. SINGAPORE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY USAGE SETTING, 2018-2030 (USD MILLION)
TABLE 266. SINGAPORE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. SINGAPORE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 268. SOUTH KOREA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 269. SOUTH KOREA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CLINICAL MICROBIOLOGY TESTING, 2018-2030 (USD MILLION)
TABLE 270. SOUTH KOREA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 271. SOUTH KOREA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEROLOGY & IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 272. SOUTH KOREA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 273. SOUTH KOREA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ADVANCED DIAGNOSTIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 274. SOUTH KOREA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TRADITIONAL DIAGNOSTIC TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 275. SOUTH KOREA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 276. SOUTH KOREA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
TABLE 277. SOUTH KOREA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY ACUTE RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 278. SOUTH KOREA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY CHRONIC RESPIRATORY CONDITIONS, 2018-2030 (USD MILLION)
TABLE 279. SOUTH KOREA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY USAGE SETTING, 2018-2030 (USD MILLION)
TABLE 280. SOUTH KOREA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. SOUTH KOREA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILL

Companies Mentioned

  • Abbott Laboratories
  • AccuBioTech Co. Ltd.
  • Atomo Diagnostics Ltd.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories Inc.
  • bioMerieux SA
  • BIORON Diagnostics GmbH
  • Cardinal Health Inc.
  • Chembio Diagnostics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Merck KGaA
  • Meridian Bioscience Inc. by SD Biosensor
  • Quest Diagnostics Incorporated
  • Quidel Corporation

Methodology

Loading
LOADING...

Related Topics

Related Reports

Respiratory Diagnostics Market by Product & Services (Instrument & Devices), Test Type (Mechanical, OSA, Imaging, Molecular Test), Disease (Tuberculosis, COPD, Lung Cancer) and Diagnosis Type (Syndromic, Aetiological, Prognosis) - Global Forecast to 2030 - Product Image

Respiratory Diagnostics Market by Product & Services (Instrument & Devices), Test Type (Mechanical, OSA, Imaging, Molecular Test), Disease (Tuberculosis, COPD, Lung Cancer) and Diagnosis Type (Syndromic, Aetiological, Prognosis) - Global Forecast to 2030

  • Report
  • 404 Pages
  • Global
From
Global Respiratory Disease Testing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Global Respiratory Disease Testing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 120 Pages
  • Global
From
Human Metapneumovirus Diagnostics Market Size, Share & Trends Analysis Report By Technology (PCR Based Diagnostics, Microarray Technology), By End-use (Hospitals & Clinics, Diagnostic & Reference Laboratories), By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Human Metapneumovirus Diagnostics Market Size, Share & Trends Analysis Report By Technology (PCR Based Diagnostics, Microarray Technology), By End-use (Hospitals & Clinics, Diagnostic & Reference Laboratories), By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 160 Pages
  • Global
From
Human Metapneumovirus Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Human Metapneumovirus Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
Respiratory Diagnostics - Global Strategic Business Report - Product Image

Respiratory Diagnostics - Global Strategic Business Report

  • Report
  • 174 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.